Screening for Type 2 diabetes mellitus: A decision analytic approach

Diabetic Medicine

Volumn 17, Issue 6, 2000, Pages 469-477

  Goyder, Elizabeth C ^a,b   Irwig, L M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Decision analysis; QALYs; Screening; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE;

ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR RISK; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SCREENING; STATISTICAL ANALYSIS;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DECISION TREES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; HUMANS; LIFE EXPECTANCY; MASS SCREENING; MIDDLE AGED;

EID: 0033914017     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00308.x     Document Type: Article

References (34)

1. 1 World Health Organisation. Prevention of Diabetes Mellitus: Report of a WHO study Group. Technical Report Series No. 844. Geneva: World Health Organization, 1994.
2. 2 Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care 16-23. Ottawa: Canada Communication Group, 1994.
3. 3 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
4. 4 Paterson KR. Population screening for diabetes mellitus. Diabetic Med 1993; 10: 777-781.
5. 5 New Zealand Society for the Study of Diabetes. Screening for diabetes in asymptomatic individuals. N Z Med J 1995; 108: 464-465.
6. 6 Eastman RC, Keen H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet 1997; 350: SI29-32.
7. 7 Marshall KG, Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm. Can Med Assoc J 1996; 155: 169-176.
8. 8 Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA 1994; 272: 773-780.
9. 9 Fletcher J, Hicks NR, Kay JDS, Boyd PA. Using decision analysis to compare policies for antenatal screening for Down's Syndrome. Br Med J 1995; 311: 351-356.
10. 10 US Preventive Services Task Force. Screening for adolescent idiopathic scoliosis. Policy statement. JAMA 1993; 269: 2664-2666.
11. 11 Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Opthalmology 1992; 99: 58-62.
12. 12 Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease - putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988; 31: 737-740.
13. 13 Eriksson KF, Lindgarde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991; 34: 891-898.
14. 14 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
15. 15 UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
16. 16 Pylorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
17. 17 Orchard TJ, Forrest KY-Z, Ellis D, Becker DJ. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1851-1856.
18. 18 Williams DRR, Wareham NJ, Brown DC, Byrne CD, Clarke PMS, Cox BD et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabetic Med 1995; 12: 30-35.
19. 19 Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F et al. Model of complications of NIDDM I. model construction and assumptions. Diabetes Care 1997; 20: 725-734.
20. 20 Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W et al. Model of complications of NIDDM II. analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycaemia. Diabetes Care 1997; 20: 735-744.
21. 21 Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ. Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1991; 34: 584-589.
22. 22 Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthew DR et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study. Br Med J 1998; 316: 823-828.
23. 23 Blunt BA, Barrett Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. Rancho Bernardo Study. Diabetes Care 1991; 14: 989-993.
24. 24 Modan M, Halkin H, Karasik A, Lusky A. Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. Am J Epidemiol 1984; 119: 431-444.
25. 25 Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. JAMA 1997; 278: 1663-1669.
26. 26 Fuller J, Stevens LK, Chaturvedi N, Holloway JF. Antihypertensive therapy in diabetes mellitus. (Cochrane Review.) In The Cochrane Library, Issue 2. Oxford: Update Software, 1998.
27. 27 Curb JD, Pressel SL, Jeffrey AC, Savage PJ, Applegate WB, Black H et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-1892.
28. 28 Murray CJL, Lopez AD. The Global Burden of Disease. a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard School of Public Health, 1996.
29. 29 Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593-600.
30. 30 Goyder EC, Irwig L. Screening for Type 2 Diabetes: a Decision Analysis Approach. Sydney: New South Wales Health Department, 1998.
31. 31 Moskowitz AJ, Dunn VH, Lau J, Pauker SG. Can 'hypersimplified' decision trees be used instead of Markov models? Med Decis Making 1984; 4: 530.
32. 32 Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 5 - Working with Markov processes. Med Decis Making 1997; 152: 152-159.
33. 33 CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998; 280: 1757-1763.
34. 34 Balkau B, Shipley M, Jarrett RJ, Pylora K, Pylora M, Forhan A et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20 year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.